Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.90 +0.45 (+1.70%)
Streaming Delayed Price Updated: 12:50 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Amphastar Director Sells 16,679 Shares for $441,800 ↗
Amphastar is down big in 2025, but recently announced positive FDA-related news. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... 
Via StockStory
Topics Stocks
News headline image
Amphastar Announces FDA Approval for Teriparatide Injection
Via ACCESS Newswire
News headline image
2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.7% in the afternoon session after positive analyst sentiment and technical trading indicators pointed to potential... 
Via StockStory
Topics Economy
News headline image
Amphastar (AMPH) Q3 2025 Earnings Call Transcript ↗
Amphastar (AMPH) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
Via ACCESS Newswire
News headline image
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks
Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
5 Must-Read Analyst Questions From Amphastar Pharmaceuticals’s Q3 Earnings Call
Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was... 
Via StockStory
Topics Earnings
News headline image
Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESS Newswire
News headline image
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP... 
Via StockStory
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst... 
Via StockStory
Topics Artificial Intelligence Economy Government
News headline image
The Analyst Verdict: Amphastar Pharma In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
Via ACCESS Newswire
News headline image
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
News headline image
1 of Wall Street’s Favorite Stock to Target This Week and 2 That Underwhelm
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Economy
News headline image
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
Via ACCESS Newswire
News headline image
2 Reasons AMPH is Risky and 1 Stock to Buy Instead
Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period. 
Via StockStory
Topics Economy Government Stocks
News headline image
Demystifying Amphastar Pharma: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.